Comparison of irinotecan and oxaliplatin as adjuvant chemotherapy for patients with resectable synchronous colon cancer plus liver-confined metastases: A retrospective nationwide database study.

Authors

Yi-Hsin Liang

National Taiwan University Hospital, Taipei, Taiwan

Yi-Hsin Liang , Yu Yun Shao , Ho-Min Chen , Ann-Lii Cheng , Mei-Shu Lai , Kun-Huei Yeh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.

First Author: Sherise C. Rogers

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).

First Author: Sherise C. Rogers

insert_chart_outlined

Poster

2020 Gastrointestinal Cancers Symposium

bookmark_border

A phase II, open-label pilot study evaluating the safety and activity of Nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study) (NCT03483038).

First Author: Hiral D. Parekh

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial).

First Author: Jaafar Bennouna